SSA
NAGE

Schonfeld Strategic Advisors’s Niagen Bioscience NAGE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,601
Closed -$51.2K – 3125
2026
Q1 		$51.2K Buy
+11,601
New +$62.6K ﹤0.01% 1960
2025
Q1 		– Sell
-12,700
Closed -$67.4K – 2569
2024
Q4 		$67.4K Buy
+12,700
New +$69.5K ﹤0.01% 1861
2022
Q3 		– Sell
-15,310
Closed -$25K – 3217
2022
Q2 		$25K Buy
+15,310
New +$29.9K ﹤0.01% 2285

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Schonfeld Strategic Advisors's NAGE Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Niagen Bioscience (NAGE) in Q2 2026, closing a stake of 11,601 shares — an estimated $51.2K sold.

Schonfeld Strategic Advisors first reported a position in NAGE in Q2 2022 and held it in 3 quarters. The position peaked at $67.4K in Q4 2024. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Niagen Bioscience position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 11,601 Niagen Bioscience shares in Q2 2026, an estimated $51.2K.
  • Schonfeld Strategic Advisors first reported a position in Niagen Bioscience in Q2 2022 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Niagen Bioscience position peaked at $67.4K in Q4 2024.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.